Johnson & Johnson (JNJ) says 2-year ICOTYDE data in moderate-to-severe plaque psoriasis showed sustained efficacy through week 112
Newsquawk Staff ·
Johnson & Johnson (JNJ) says 2-year ICOTYDE data in moderate-to-severe plaque psoriasis showed sustained efficacy through week 112.
What it means
Long-term extension data of this kind is a durability read rather than an efficacy surprise: by the time a candidate reaches week 112 follow-up, the pivotal efficacy question has usually been settled, and what the longer dataset addresses is whether the treatment effect holds and whether safety signals accumulate with exposure. In dermatology specifically, sustained-response data has historically mattered most for competitive positioning within an increasingly crowded class of oral and biologic psoriasis agents, where payers and prescribers differentiate on durability and convenience as much as on headline clearance rates. The distinction worth drawing is between data that expands a label or supports a filing and data that merely reinforces an existing profile; the former moves estimates, the latter tends to be absorbed quietly. For a large diversified name like JNJ, single-asset readouts have rarely been stock-moving in isolation, with the pattern being that pipeline updates feed into franchise-level models rather than standalone repricing. Worth noting is whether the dataset is accompanied by regulatory intent, a filing timeline or congress presentation detail, since that is what converts a maintenance update into a catalyst. Absent that, this reads as incremental confirmation.
Sources
- The Mosaic Company (MOS) Q3 2026 (USD): Adj. EPS -0.19 (exp. -0.01), Revenue 3.1bln (exp. 3.05bln)
- Amgen Inc. (AMGN) Q3 2026 (USD): Adj. EPS 6.45 (exp. 5.79), Revenue 10.4bln (exp. 10.07bln), Adj. operating income 4.7bln (exp. 4.33bln)
- Newsquawk Daily US Earnings Estimates - 4th November 2026: CVS, UBER, MCD, QCOM, MCK, ARM
- US BROKER MOVES: BE upgraded at Barclays; MRVL downgraded at TD Cowen
- Pfizer (PFE) appoints Cecile Guegan as CFO and EVP, effective November 1st
Related headlines
- Arista Networks Inc. (ANET) Q3 2026 (USD): Adj. EPS 1.20 (exp. 1.08), Revenue 3.66bln (exp. 3.33bln)6 days ago
- Booking Holdings Inc. (BKNG) Q3 2026 (USD): Adj. EPS 4.66 (exp. 4.49), Revenue 8.9bln (exp. 9.55bln)6 days ago
- Oracle (ORCL) executive VP told Nikkei the Co. has no plans to slow down its investment in Japan, emphasising that the country remains a key market6 days ago
- Ambani’s Jio Platforms held talks to license technology to Comcast (CMCSA) and Charter (CHTR) in exchange for shares, according to sources6 days ago
- Uber’s (UBER) Jill Hazelbaker to join OpenAI as Chief Corporate Affairs Officer, reports The Information6 days ago
- Apple (AAPL) opens Siri AI preview to all developers6 days ago
- Nvidia’s (NVDA) market dominance helps it influence policy and customers, reports The Information6 days ago
- Sysco (SYY) executives expect basket inflation below 1% in Q2 and between 1% and 1.5% for the full year, down from its budgeted 1.5-2% assumption, creating near term P&L pressure6 days ago
- US EQUITY OPEN: Tech pares back some recent losses as US/Iran negotiations and US midterms are in focus6 days ago
- Spanish competition authority (CNMC) launches disciplinary proceedings against Apple (AAPL) and Amazon (AMZN)6 days ago
- Amazon's (AMZN) AWS and GOSH are to deploy emerging technologies in healthcare6 days ago
- Williams (WMB) says elections are not expected to delay data center projects6 days ago
- Pershing Square's Bill Ackman says Netflix (NFLX) stock is 'incredibly cheap'6 days ago
- US PRE-MARKET MOVERS: AAPL, PLTR, ON, FN, LSCC, SHOP, KDP, FISV, DD6 days ago
- Keurig Dr Pepper Inc. (KDP) Q3 2026 (USD): Adj. EPS 0.66 (exp. 0.62), Revenue 7.3bln (exp. 7.33bln), Adj. operating income 1.7bln (exp. 1.6bln); reaffirms guidance6 days ago